Connect with us


Legalisation linked to fewer synthetic cannabinoid poisonings

Synthetic cannabinoids appear to have less appeal in states which have legalised natural cannabis.



Cannabis-dependent patients may be at risk of post-surgery complications - study

New research shows a reduction in reports of synthetic cannabinoid poisonings in US states where cannabis has been legalised.

Synthetic cannabinoids, known by such street names as K2, Spice or AK-47, appear to have less appeal in states that have legalised the natural form of cannabis, according to a new study. 

A Washington State University-led study found a 37 per cent drop in poisoning reports for illicit synthetic cannabinoids, which are hard to detect using standard drug tests, in states with legal recreational or “adult use” cannabis compared to states with restrictive policies.

Synthetic cannabinoids are not actually cannabis. They are so named because they work on the same cannabinoid receptors in the brain as the psychoactive component in the cannabis plant, tetrahydrocannabinol or THC. 

Yet the illicit synthetics bind with those receptors up to 100 times more strongly and lack any of the mediating constituents of whole-plant cannabis such as cannabidiol or CBD. 

As a result, synthetic cannabinoids have a high toxicity and can lead to severe impairment, even death.

For this study, published in the Journal of Clinical Toxicology, researchers analysed data from the National Poison Data System from 2016 to 2019, before the onset of the pandemic. 

They looked only at states that had relatively stable policies during those years, placing them in one of three categories: permissive like Washington state, allowing both medical and recreational adult use of cannabis, medical like Hawaii, permitting cannabis only for medical use, or restrictive like Idaho, prohibiting nearly all cannabis use.

In this sample, there were 7,600 calls to poisoning reports related to synthetic cannabinoid use, about 65 per cent of which required medical attention. There were also 61 deaths. 

The researchers found that synthetic-related poisoning reports went down overall during this time period, but there were 13 per cent fewer in medical states and a much more significant drop off of 37 per cent in permissive states.

Lead author Tracy Klein, a WSU associate professor of nursing, commented: “This study shows some potential public health benefits to the legalisation and regulation of adult use of cannabis.

“Based on both past research and this current study, it’s evident that users who have a choice to use a less toxic product would potentially do so.”

An earlier study in JAMA Open found that poison control calls related to natural cannabis use also increased from 2017 to 2019 across the US, but were driven mainly by manufactured products, such as plant-based vaping materials and edibles, which can contain high levels of THC. In contrast, poison control calls for whole plant cannabis declined during the same time period.

While some synthetic cannabinoids have been made for medical use, namely dronabinol and nabilone used primarily to treat nausea associated with cancer treatment, the illicit versions are illegal in all states and have no medical purpose.

Enforcement can be difficult because makers change their formulas frequently. They are also usually undetected in standard urine drug tests – which may be one reason people in restrictive states use them.

Future research is needed to better understand the use of these drugs and the differences among them, Klein said. 

She pointed out that the study’s data set does not contain the rising popularity of synthetically derived Delta-8, marketed as a less strong form of Delta-9, which is the psychoactive cannabinoid found in naturally produced plant products.

“We know that there are many cannabinoids being developed and on the market – and the regulators are struggling to catch up,” said Klein, who is also the assistant director of WSU’s Center for Cannabis Policy, Research and Outreach.

The current study likely underestimates the use of these drugs, the authors note, because the drugs are difficult to detect.

Klein added: “You can’t easily test for illicit cannabinoids. A lot of times, we only find out if a patient has been using them because they’re hospitalised or because they’re dead.”

Home » Science » Legalisation linked to fewer synthetic cannabinoid poisonings

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.